Literature DB >> 16044256

The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria.

Seiko Sanada1, Toshihiko Tanaka, Yoshikazu Kameyoshi, Michihiro Hide.   

Abstract

Many patients with chronic idiopathic urticaria are not sufficiently controlled with histamine H(1)-receptor antagonists. Leukotriene receptor antagonists have been reported to be effective for certain cases of urticaria, although their proper application remains to be established. To study the effectiveness of montelukast, a leukotriene receptor antagonist, for the treatment of chronic urticaria that was not controlled by histamine H(1)-receptor antagonists. Twenty-five patients with chronic idiopathic urticaria were treated with 10 mg of montelukast for one week or more, without changing any precedent treatment that they were using before the study including histamine H(1)-receptor antagonists. The effectiveness of montelukast for each patient was evaluated and compared with clinical features and/or backgrounds of the patients. Twelve patients, including six who had been treated with corticosteroids, were evaluated as "markedly improved" or "improved" following treatment with montelukast. There was no statistically significant relation of the effectiveness to the complications with non-steroidal anti-inflammatory drugs (NSAIDs) intolerance, mechanical urticaria, or reactions to autologous serum skin test. However, the patients for whom montelukast was effective were younger (33.2+/-16.3 years, mean +/- SD)(P<0.05, Mann-Whitney test) and their duration of illness shorter (15.9+/-18.3 months) (P<0.005, Mann-Whitney test) than those of patients for whom montelukast was ineffective (45.9+/-15.0 years, 89.6+/-71.7 months). Montelukast may be worth trying for patients with chronic idiopathic urticaria, when the condition is not sufficiently controlled with histamine H(1)-receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044256     DOI: 10.1007/s00403-005-0586-4

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  7 in total

1.  Use of, satisfaction with, and willingness to switch prescription and over-the-counter treatments for chronic urticaria: an online survey.

Authors:  Donald E Stull; Sonia Gavriel
Journal:  Patient       Date:  2009-09-01       Impact factor: 3.883

Review 2.  Chronic Urticaria: Comparisons of US, European, and Asian Guidelines.

Authors:  S Shahzad Mustafa; Mario Sánchez-Borges
Journal:  Curr Allergy Asthma Rep       Date:  2018-05-24       Impact factor: 4.806

Review 3.  Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines.

Authors:  Lauren M Fine; Jonathan A Bernstein
Journal:  Curr Allergy Asthma Rep       Date:  2015-06       Impact factor: 4.806

4.  Contact urticaria: present scenario.

Authors:  Ruchi Bhatia; Ali Alikhan; Howard I Maibach
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

Review 5.  The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field.

Authors:  Eustachio Nettis; Maddalena D'Erasmo; Elisabetta Di Leo; Gianfranco Calogiuri; Vincenzo Montinaro; Antonio Ferrannini; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2010-09-22       Impact factor: 4.711

Review 6.  Montelukast in pediatric asthma management.

Authors:  Mandeep Walia; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 1.967

7.  Gomisin M2 Inhibits Mast Cell-Mediated Allergic Inflammation via Attenuation of FcεRI-Mediated Lyn and Fyn Activation and Intracellular Calcium Levels.

Authors:  Hima Dhakal; Soyoung Lee; Eun-Nam Kim; Jin Kyeong Choi; Min-Jong Kim; Jinjoo Kang; Young-Ae Choi; Moon-Chang Baek; Byungheon Lee; Hyun-Shik Lee; Tae-Yong Shin; Gil-Saeng Jeong; Sang-Hyun Kim
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.